Pharmaceutical Industry discussion, review, analysis, news and information.

According to the results presented during the 131st Annual Meeting of the American Neurological Association (ANA), Schwarz Pharma's rotigotine transdermal patch showed a favorable safety and tolerability profile for the treatment of Parkinson's Disease in patients over the age of 75.

Use of dopamine agonists in the over 75 population is often limited because of the potential for increased adverse reactions. The combined analysis presented included early-stage Parkinson's disease (PD) patients up to 86 years of age. This data showed that the transdermal dopamine agonist, rotigotine, may be a useful treatment option in both relatively younger and older PD patients.

The Neupro® rotigotine patch is still under review with the US FDA, but has already been approved in the EU, as monotherapy for early-stage PD. An application for rotigotine for the treatment of advanced-stage PD was submitted in Europe earlier this year.

Source: PharmaLive